Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › EloraTZP

EloraTZP

GIP/GLP-1 + amylin · s.c. · Eli Lilly

Data cut 12 November 2026 · page built 16 November 2026 · 4 trial arms · 1 trials with results · 2 registered trials · see on the pipeline board

Summary

Also known as
eloralintide + tirzepatide, Eli Lilly
Mechanism
GIP/GLP-1 + amylin
Route
s.c.
Company
Eli Lilly
Highest development stage
phase 3
Status (as of data cut)
Phase 2b in obesity with T2D positive (Sep 2026: up to −23.3 % vs −14.8 % with tirzepatide 15 mg); phase 3 AMPLIFY-1 and AMPLIFY-2 registered (100 weeks, start Q4 2026) verify
Next milestone
AMPLIFY phase 3 start

Sources for the status

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
EloraTZP phase 2b (obesity + T2D)EloraTZP 3/5 mgt2d48—−13.2 % vs −3.0 %
Δ −10.2 pp
—−2.2 vs −0.3——————press release
EloraTZP phase 2b (obesity + T2D)EloraTZP 6/5 mgt2d48—−19.4 % vs −3.0 %
Δ −16.4 pp
—−2.7 vs −0.3——————press release
EloraTZP phase 2b (obesity + T2D)EloraTZP 6/10 mgt2d48—−19.9 % vs −3.0 %
Δ −16.9 pp
—−2.6 vs −0.3——————press release
EloraTZP phase 2b (obesity + T2D)EloraTZP 9/15 mgt2d48—−23.3 % vs −3.0 %
Δ −20.3 pp
—−2.9 vs −0.3——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (4)
  • EloraTZP 3/5 mg · weight_eff · press release table
    Elora 3 mg + TZP 5 mg -13.2
  • EloraTZP 6/5 mg · weight_eff · press release table
    Elora 6 mg + TZP 5 mg -19.4
  • EloraTZP 6/10 mg · weight_eff · press release table
    Elora 6 mg + TZP 10 mg -19.9
  • EloraTZP 9/15 mg · weight_eff · press release table
    Elora 9 mg + TZP 15 mg -23.3

Registered trials (2)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
AMPLIFY-1
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
ObesityPhase 3not yet recruiting2026-12 → 2029-102115not yet recruitingNCT07881432
AMPLIFY-2
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
ObesityPhase 3recruiting2026-10 → 2029-101000recruitingNCT07881458

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: EloraTZP. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/eloratzp/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.